The global pharmaceutical industry experienced an 11% drop in new job postings related to precision and personalized medicine in Q2 2023 compared with the previous quarter, according to GlobalData’s Job Analytics. This compares to 0.64% decrease versus Q2 2022. Buy the report here.
Notably, Life, Physical, and Social Science Occupations jobs accounted for a 24% share of the global pharmaceutical industry’s precision and personalized medicine-related total new job postings in Q2 2023, down 25% over the prior quarter.
Life, Physical, and Social Science Occupations drive precision and personalized medicine-related hiring activity
Life, Physical, and Social Science Occupations, with a share of 24%, emerged as the top precision and personalized medicine-related job roles within the pharmaceutical industry in Q2 2023, with new job postings drop by 25% quarter-on-quarter. Management Occupations came in second with a share of 20% in Q2 2023, with new job postings dropping by 27% over the previous quarter.
The other prominent precision and personalized medicine roles include Computer and Mathematical Occupations with a 6% share in Q2 2023, Healthcare Practitioners and Technical Occupations with a 6% share of new job postings.
Top five companies in pharmaceutical industry accounted for 53% of hiring activity
The top companies, in terms of number of new job postings tracked by GlobalData, as of Q2 2023 were AbbVie, AstraZeneca, Sarepta Therapeutics, F. Hoffmann-La Roche, and Novartis. Together they accounted for a combined share of 53% of all precision and personalized medicine-related new jobs in the pharmaceutical industry.
AbbVie posted 529 precision and personalized medicine-related new jobs in Q2 2023, AstraZeneca 90 jobs, Sarepta Therapeutics 74 jobs, F. Hoffmann-La Roche 69 jobs, and Novartis 62 jobs, according to GlobalDataâ€™s Job Analytics.
Hiring activity was driven by the US with a 75.71% share of total new job postings, Q2 2023
The largest share of precision and personalized medicine-related new job postings in the pharmaceutical industry in Q2 2023 was in the US with 75.71% followed by the UK (2.91%) and Germany (2.40%). The share represented by the US was five percentage points lower than the 81.11% share it accounted for in Q1 2023.